apixaban

Blood thinners cut strokes in people with AF at a middling risk

The SINGLE-AF trial found apixaban or rivaroxaban cut serious events from 1.5% to 0.5% in AF patients at intermediate stroke risk, without more major bleeding.

28 August 2026